The US National Institutes of Health have awarded $3.4 million to GlycoVaxyn AG of Switzerland and a researcher at the Harvard Medical School to carry out preclinical work on a new S. aureus vaccine for hospital-acquired infections. ---Subscribe to MedNous to access this article--- Research & University News Finance, Grants, Deals Company News
